A questão das 12 doses da poliquimioterapia para a hanseníase

Diltor Vladimir Araújo Opromolla

doi:10.47878/hi.1999.v24.36422

Autores/as

Diltor Vladimir Araújo Opromolla Médico dermatologista e Diretor da Divisão de Pesquisa e Ensino do Instituto Lauro de Souza Lima - Secretaria de Estado da Saúde.

DOI:

https://doi.org/10.47878/hi.1999.v24.36422

Resumen

.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

1. BRACKEL, Win H. Van Proposal regarding MDT. Leprosy Review, v.70, p.71-72, March, 1999. (Letters to the Editor).
2. INTERNATIONAL LEPROSY CONGRESS, 25, Beijing, 1998. Reports. Beijing, China: The International Leprosy Association, 1998.
3. JAMET, Pierre, JI Baohong. Releapse after- long up of multibacillary patients treated by WHO multidrug regimen. International Journal of Leprosy, v.63, no 2, p.195-201, June, 1995.
4. JI Baohong. Why multidrug therapy for multibacilalry leprosy can be shortned to 12 months. Leprosy Review, v.69, no ,2, p.106-109, March, 1998. (Editorial).
5. LYNCH, Patrick. Multdurg therapy. Leprosy Review, v.70, p.70-71, March, 1999. (Letters to the Editor).
6. McDOUGALL, A. Colin. Recent development in the chemotherapy of leprosy. Leprosy Review, v.68, no 4, p.294-298, December, 1997. (Editorial).
7. WATERS, M. Is it safe to shorten multidrug therapy for lepromatous (LL and BL) leprosy to 12 months. Leprosy Review, v.69, no ,2, p.110-111, March, 1998. (Commentary).
8. WHO Expert Commitee on Leprosy, Seventh report. WHO technical report Series, no 874. World Health Organization, Geneva 1998.
9. WHO Study Group. Chemoheapy of leprosy. WHO technical report Series, rig 847. World Health Organization, Geneva 1994.